{"success":true,"data":{"pressRelease":{"id":"69730","rtpr_id":"nGNX8FHSvl","ticker":"1BTG","exchange":"","all_tickers":["1BTG"],"title":"Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion","author":"Globe Newswire","published_at":"2026-06-22T12:45:00.156Z","article_body":"*   As of June 18, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total\nvalue of approximately $1.14 billion(1).\nNes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq:\nENLV, \"Enlivex\" or the \"Company\"), a quality longevity company powered by a\nprediction markets treasury, today provided an update on its RAIN token\nholdings. As of June 20, 2026, the Company held 79,568,550,005 RAIN tokens\nwith a total value of approximately $1.14 billion(1).\n\nThe Company's treasury metrics, as reflected on its public market data\ndashboard, indicate a Treasury NAV per Share of $4.67(1) as of June 20, 2026,\nbased on current RAIN token holdings relative to total number of the\nCompany’s ordinary shares outstanding. The updated unaudited mark-to-market\ntreasury metrics are publicly available on the Company's website at\nhttps://enlivex.com/dashboard/. Detailed information about the token’s\nlisting on various exchanges, daily trading volume and other parameters can be\nfound on https://coinmarketcap.com/currencies/rain/.  \n\nAbout Enlivex\n\nEnlivex is a quality longevity company powered by a prediction markets\ntreasury. The Company is advancing Allocetra™, an advanced clinical-stage\nimmunotherapy targeting inflammatory conditions associated with aging, with a\nprimary focus on age-related osteoarthritis. In addition to its clinical\nprograms, Enlivex operates a prediction markets treasury strategy built around\nthe Rain protocol, the leading decentralized prediction markets infrastructure\non Arbitrum. This dual strategy combines the development of quality longevity\ntherapeutics with exposure to the emerging prediction markets ecosystem.\n\nForward-looking statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. These forward-looking statements\nmay be identified by words such as \"expects,\" \"plans,\" \"projects,\" \"will,\"\n\"may,\" \"anticipates,\" \"believes,\" \"should,\" \"would,\" \"could,\" \"intends,\"\n\"estimates,\" \"suggests,\" \"target,\" \"has the potential to,\" \"goal,\" and other\nwords of similar meaning, including statements relating to the anticipated\nbenefits of the Company's digital asset treasury strategy; the assets to be\nheld by the Company; the expected future market, price, trading activity, and\nliquidity of the RAIN token; the impact of expanded exchange listings and\nincreased token liquidity on market participation and accessibility; the\npotential effects of digital asset liquidity on the liquidity of the Company's\nordinary shares; macroeconomic, political, and regulatory conditions\nsurrounding digital assets; the Company's plans for value creation and\nstrategic positioning; market size and growth opportunities; regulatory\nconditions; competitive position; technological and market trends; future\nfinancial condition and performance; expected clinical trial results; market\nopportunities for the results of current clinical studies and preclinical\nexperiments; and the effectiveness of, and market opportunities for,\nALLOCETRA™ programs.\n\nEach forward-looking statement contained in this press release is subject to\nrisks and uncertainties that could cause actual results to differ materially\nfrom those expressed or implied by such statement. Applicable risks and\nuncertainties include, among others, the risk of failure to realize the\nanticipated benefits of the Company's digital asset treasury strategy; changes\nin business, market, financial, political, and regulatory conditions; risks\nrelating to the Company's operations and business, including the highly\nvolatile nature of the price, trading volume, and liquidity of RAIN and other\ncryptocurrencies; risks associated with digital asset exchange listings,\ntrading venues, and market infrastructure; the risk that the price and\nliquidity of the Company's ordinary shares may be correlated with the price or\nliquidity of the digital assets it holds; risks related to increased\ncompetition in the industries in which the Company operates; risks relating to\nsignificant legal, commercial, regulatory, and technical uncertainty regarding\ndigital assets generally; risks relating to the treatment of crypto assets for\nU.S. and foreign tax purposes; and those risks and uncertainties identified in\nthe Company's filings with the Securities and Exchange Commission. The\nforward-looking statements in this press release speak only as of the date of\nthis document, and the Company undertakes no obligation to update or revise\nany of these statements, except as required by applicable law.\n\nEnlivex contact\n\nShachar Shlosberger\nCFO\nEnlivex Ltd.\nshachar@enlivex.com\n\n\n\n\n\n(1) Valuation calculated using the closing price of the token as quoted on\nhttps://coinmarketcap.com/currencies/rain/\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/27d4e006-8709-4fd1-8341-5b58381487d4)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8FHSvl","title":"Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion","author":"Globe Newswire","ticker":"1BTG","created":"2026-06-22T12:45:00.156Z","tickers":["1BTG"],"exchange":"","article_body":"*   As of June 18, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total\nvalue of approximately $1.14 billion(1).\nNes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq:\nENLV, \"Enlivex\" or the \"Company\"), a quality longevity company powered by a\nprediction markets treasury, today provided an update on its RAIN token\nholdings. As of June 20, 2026, the Company held 79,568,550,005 RAIN tokens\nwith a total value of approximately $1.14 billion(1).\n\nThe Company's treasury metrics, as reflected on its public market data\ndashboard, indicate a Treasury NAV per Share of $4.67(1) as of June 20, 2026,\nbased on current RAIN token holdings relative to total number of the\nCompany’s ordinary shares outstanding. The updated unaudited mark-to-market\ntreasury metrics are publicly available on the Company's website at\nhttps://enlivex.com/dashboard/. Detailed information about the token’s\nlisting on various exchanges, daily trading volume and other parameters can be\nfound on https://coinmarketcap.com/currencies/rain/.  \n\nAbout Enlivex\n\nEnlivex is a quality longevity company powered by a prediction markets\ntreasury. The Company is advancing Allocetra™, an advanced clinical-stage\nimmunotherapy targeting inflammatory conditions associated with aging, with a\nprimary focus on age-related osteoarthritis. In addition to its clinical\nprograms, Enlivex operates a prediction markets treasury strategy built around\nthe Rain protocol, the leading decentralized prediction markets infrastructure\non Arbitrum. This dual strategy combines the development of quality longevity\ntherapeutics with exposure to the emerging prediction markets ecosystem.\n\nForward-looking statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. These forward-looking statements\nmay be identified by words such as \"expects,\" \"plans,\" \"projects,\" \"will,\"\n\"may,\" \"anticipates,\" \"believes,\" \"should,\" \"would,\" \"could,\" \"intends,\"\n\"estimates,\" \"suggests,\" \"target,\" \"has the potential to,\" \"goal,\" and other\nwords of similar meaning, including statements relating to the anticipated\nbenefits of the Company's digital asset treasury strategy; the assets to be\nheld by the Company; the expected future market, price, trading activity, and\nliquidity of the RAIN token; the impact of expanded exchange listings and\nincreased token liquidity on market participation and accessibility; the\npotential effects of digital asset liquidity on the liquidity of the Company's\nordinary shares; macroeconomic, political, and regulatory conditions\nsurrounding digital assets; the Company's plans for value creation and\nstrategic positioning; market size and growth opportunities; regulatory\nconditions; competitive position; technological and market trends; future\nfinancial condition and performance; expected clinical trial results; market\nopportunities for the results of current clinical studies and preclinical\nexperiments; and the effectiveness of, and market opportunities for,\nALLOCETRA™ programs.\n\nEach forward-looking statement contained in this press release is subject to\nrisks and uncertainties that could cause actual results to differ materially\nfrom those expressed or implied by such statement. Applicable risks and\nuncertainties include, among others, the risk of failure to realize the\nanticipated benefits of the Company's digital asset treasury strategy; changes\nin business, market, financial, political, and regulatory conditions; risks\nrelating to the Company's operations and business, including the highly\nvolatile nature of the price, trading volume, and liquidity of RAIN and other\ncryptocurrencies; risks associated with digital asset exchange listings,\ntrading venues, and market infrastructure; the risk that the price and\nliquidity of the Company's ordinary shares may be correlated with the price or\nliquidity of the digital assets it holds; risks related to increased\ncompetition in the industries in which the Company operates; risks relating to\nsignificant legal, commercial, regulatory, and technical uncertainty regarding\ndigital assets generally; risks relating to the treatment of crypto assets for\nU.S. and foreign tax purposes; and those risks and uncertainties identified in\nthe Company's filings with the Securities and Exchange Commission. The\nforward-looking statements in this press release speak only as of the date of\nthis document, and the Company undertakes no obligation to update or revise\nany of these statements, except as required by applicable law.\n\nEnlivex contact\n\nShachar Shlosberger\nCFO\nEnlivex Ltd.\nshachar@enlivex.com\n\n\n\n\n\n(1) Valuation calculated using the closing price of the token as quoted on\nhttps://coinmarketcap.com/currencies/rain/\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/27d4e006-8709-4fd1-8341-5b58381487d4)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-22T12:45:00.21550172Z","server_sent_at_ms":1782132300215},"received_at":"2026-06-22T12:45:00.268Z","source_url":"https://www.globenewswire.com/news-release/2026/06/22/3315295/0/en/Enlivex-Treasury-Portfolio-Update-RAIN-Holdings-Valued-at-Approximately-1-14-Billion.html"},"analysis":{"id":"59128","press_release_id":"69730","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["High concentration risk in single crypto asset (RAIN tokens)","NAV per share derived from volatile crypto pricing"],"eventType":"operations_update","narrative":"Enlivex reported that as of June 20, 2026, it held approximately 79.57 billion RAIN tokens with a total value of roughly $1.14 billion.\n\nThe company's unaudited Treasury NAV per Share is calculated at $4.67 based on the current mark-to-market value of its digital asset holdings.\n\nEnlivex operates a dual strategy focusing on clinical-stage immunotherapy Allocetra™ alongside its prediction markets treasury strategy built on the Rain protocol.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Treasury update highlights $1.14B RAIN position; NAV pegged at $4.67."},"keyFigures":{"customDimensions":{"nav_per_share":"$4.67","token_holdings":79568550005,"treasury_value":"$1.14 billion","valuation_date":"June 20, 2026"}},"quotedText":"","namedEntities":{"people":[{"name":"Shachar Shlosberger","role":"CFO"}],"products":["Allocetra™","RAIN token","Rain protocol"],"companies":[{"name":"Enlivex Ltd.","ticker":"ENLV","relationship":"issuer_mentioned_in_article"}],"dollarAmounts":[{"amount":"$1.14 billion","context":"total value of RAIN token holdings"},{"amount":"$4.67","context":"Treasury NAV per Share"}]},"materialImpact":{"score":2,"reasoning":"Routine treasury update disclosing mark-to-market valuation and NAV per share. While the asset value is significant, the event is a periodic status update rather than a market-moving binary event."},"tickerRelevance":{"others":[{"ticker":"ENLV","relevance":"mentioned_in_article"}],"primary":"1BTG"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small_micro_cap","eventGravity":"treasury_update","sectorWeight":"hybrid_biotech_crypto"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Enlivex reported that as of June 20, 2026, it held approximately 79.57 billion RAIN tokens with a total value of roughly $1.14 billion.\n\nThe company's unaudited Treasury NAV per Share is calculated at $4.67 based on the current mark-to-market value of its digital asset holdings.\n\nEnlivex operates a dual strategy focusing on clinical-stage immunotherapy Allocetra™ alongside its prediction markets treasury strategy built on the Rain protocol.","key_figures":{"customDimensions":{"nav_per_share":"$4.67","token_holdings":79568550005,"treasury_value":"$1.14 billion","valuation_date":"June 20, 2026"}},"named_entities":{"people":[{"name":"Shachar Shlosberger","role":"CFO"}],"products":["Allocetra™","RAIN token","Rain protocol"],"companies":[{"name":"Enlivex Ltd.","ticker":"ENLV","relationship":"issuer_mentioned_in_article"}],"dollarAmounts":[{"amount":"$1.14 billion","context":"total value of RAIN token holdings"},{"amount":"$4.67","context":"Treasury NAV per Share"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-22T13:04:19.313Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small_micro_cap","eventGravity":"treasury_update","sectorWeight":"hybrid_biotech_crypto"}},"durationMs":142116,"modelName":"george-droid-qwen-72b"}}